Article
MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity.
Cancer biology & therapy - 1 May 2010
Leung Euphemia, Kannan Nagarajan, Krissansen Geoffrey W, Findlay Michael P, Baguley Bruce C
Abstract excerpt
Patients with estrogen receptor-positive (ER+) breast cancers are often treated with aromatase inhibitors or by antiestrogens such as tamoxifen to prevent disease recurrence. Resistant tumors nevertheless develop and it is commonly assumed that they arise by the induction of mutations. However, it is also possible that resistant tumors grow from preexisting variant populations within the original tumor. We have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.